微生物相关肿瘤的发病机制及其治疗的研究进展

doi:10.16352/j.issn.1001-6325.2023.01.0178

摘要/Abstract

摘要： 肿瘤是多因素参与和多阶段发病的疾病,其中生物致癌因素主要有致癌性病毒、细菌及寄生虫,常见的包括乙型肝炎病毒(HBV)与肝细胞癌、EB病毒(EBV)与鼻咽癌、人乳头瘤病毒(HPV)与宫颈癌、幽门螺杆菌(Hp)与MALT淋巴瘤及胃癌等。肿瘤的发生发展与微生物密不可分,微生物可通过以下几种机制施展致癌促癌作用: 产生毒性物质、诱导毒性效应、诱导炎性反应发生、影响免疫应答等。本文将微生物的致癌促癌机制相关进展做简要总结,并展望以微生物作为早期肿瘤筛查的生物标志物和以微生物作为靶点研发药物的新思路。

关键词: 微生物, 肿瘤, 发病机制, 早期筛查, 治疗

Abstract: Tumor is a disease with multi-factor participation and multi-stage onset, among which the biological carcinogenic factors are mainly carcinogenic viruses, bacteria and parasites, and the common ones include hepatitis B virus(HPV) and hepatocellular carcinoma, Epstein-Barr virus(EBV) and nasopharyngeal carcinoma, human papilloma virus(HPV) and cervical cancer, Helicobacter pylori and MALT lymphoma,gastric cancer etc.The occurrence and development of certain tumors are closely related to microorganisms, which can play a role in carcinogenesis and cancer promotion through the following mechanisms:producing toxic substances, inducing toxic effects,inducing inflammation, affecting immune response, etc. This review briefly summarizes the carcinogenic and cancer-promoting mechanisms of microorganisms, and looks forward to the new ideas of using microorganisms as biomarkers for early tumor screening and developing drugs by targeting microorganisms.

Key words: microorganism, tumor, pathogenesis, early screening, treatment

中图分类号:

R730

孙慧, 陈思宇. 微生物相关肿瘤的发病机制及其治疗的研究进展[J]. 基础医学与临床, 2023, 43(1): 178-182.

SUN Hui, CHEN Siyu. Research progress of pathogenesis and treatment of microorganism-related tumors[J]. Basic & Clinical Medicine, 2023, 43(1): 178-182.

参考文献

[1] Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intra-cellular bacteria[J]. Science,2020,368:973-980.
[2] Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli[J]. Nature, 2020,580:269-273.
[3] Apopa PL, Alley L, Penney RB, et al. PARP1 is up-regulated in non-small cell lung cancer tissues in the presence of the cyanobacterial toxin microcystin[J]. Front Microbiol, 2018,9:1757-1764.
[4] Urbaniak C, Gloor GB, Brackstone M,et al.The micro-biota of breast tissue and its association with breast cancer[J]. Appl Environ Microbiol, 2016,82:5039-5048.
[5] Klinakis A, Karagiannis D, Rampias T.Targeting DNA repair in cancer: current state and novel approaches[J]. Cell Mol Life Sci, 2020,77:677-703.
[6] Alhinai EA, Walton GE, Commane DM. The role of the gut microbiota in colorectal cancer causation[J]. Int J Mol Sci, 2019,20:5295-5262.
[7] Jeon JI, Choi JH, Lee KH,et al. Bacteroides fragilis enterotoxin induces sulfiredoxin-1 expression in intestinal epithelial cell lines through a mitogen-activated protein kinases- and Nrf2-dependent pathway, leading to the suppression of apoptosis[J]. Int J Mol Sci,2020,21:5383-5390.
[8] Gu T, Li Q, Egilmez NK. IFNβ-producing CX3CR1⁺ macrophages promote T-regulatory cell expansion and tumor growth in the APCmin/+/Bacteroides fragilis colon cancer model[J/OL]. OncoImmunology,2019,8.doi:10.1080/2162402X.2019.1665975.
[9] Whisner CM, Athena Aktipis C. The role of the micro-biome in cancer initiation and progression: How microbes and cancer cells utilize excess energy and promote one another's growth[J]. Curr Nutr Rep,2019,8:42-51.
[10] Kikuchi T, Mimura K, Ashizawa M, et al. Characteriza-tion of tumor-infiltrating immune cells in relation to microbiota in colorectal cancers[J]. Cancer Immunol Immunother,2020,69:23-32.
[11] Lavoie S, Chun E, Bae S, et al. Expression of free fatty acid receptor 2 by dendritic cells prevents their expression of interleukin 27 and is required for maintenance of mucosal barrier and immune response against colorectal tumors in mice[J]. Gastroenterology,2020,158:1359-1372.
[12] Audirac-Chalifour A, Torres-Poveda K, Bahena-Román M, et al. Cervical microbiome and cytokine profile at various stages of cervical cancer: a pilot study[J/OL]. PLoS One,2016,11. doi: 10.1371/journal.pone.0153274.
[13] Zhou C,Zhou Y,Fang J.Gut microbiota in cancer immune response and immunotherapy[J]. Trends Cancer, 2021,7:647-660.
[14] Zhang X, Zhu X, Cao Y, et al. Fecal fusobacterium nucleatum for the diagnosis of colorectal tumor:a systematic review and meta-analysis[J]. Cancer Med,2019,8:480-491.
[15] Yang J, Li D, Yang Z,et al.Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families[J]. Gut Microbes, 2020,11:918-929.
[16] Coker OO, Nakatsu G, Dai RZ, et al. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer[J]. Gut,2019,68:654-662.
[17] Liang Q, Chiu J, Chen Y, et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer[J]. Clin Cancer Res,2017,23:2061-2070.
[18] Dai Z, Coker OO, Nakatsu G, et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers[J]. Microbiome, 2018,6:70-76.
[19] 李双,李明珠,丛青,等.人乳头瘤病毒疫苗临床应用中国专家共识[J].协和医学杂志,2021,12:189-201.
[20] Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of fusobacterium persistence and antibiotic response in colorectal cancer[J]. Science, 2017, 358: 1443-1448.
[21] 陆玮,肖乾,胡烨婷,等.微生物与结直肠癌的发病机制、早期诊断和治疗的研究进展[J].肿瘤防治研究,2020,47:909-914.
[22] 崔超,涂强,张友明.细菌用于靶向治疗肿瘤的研究进展[J].中国抗生素杂志,2021,46,388-395.
[23] Zhang H,Lin M,Dong C,et al.An MST4-p β-catenin Thr40 signaling axis controls intestinal stem cell and tumori-genesis[J/OL].Advanced Science,2021,8. doi: 10.1002/advs.202004850.
[24] Chen D,Jin D, Huang S, et al.Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota[J]. Cancer Lett, 2020,469:456-467.
[25] 蒋如如,李欣,李洁,等.减毒沙门氏菌在抗肿瘤治疗中的应用[J].基础医学与临床,2019,39:1356-1360.
[26] 王淑梅,邸维,妥彦峰.益生菌的免疫调控作用研究进展[J].粮食与油脂,2021,34:23-26.
[27] Górska A, Przystupski D, Niemczura MJ,et al. Probiotic bacteria: a promising tool in cancer prevention and therapy[J].Curr Microbiol,2019,76:939-949.
[28] Badgeley A, Anwar H, Modi K,et al. Effect of probiotics and gut microbiota on anti-cancer drugs: mechanistic perspectives[J]. Biochim Biophys Acta Rev Cancer, 2021,1875:188494.doi:10.1016/j.bbcan.2020.188494.
[29] Lin S, Mukherjee S,Li J, et al.Mucosal immunity-mediated modulation of the gut microbiome by oral delivery of probiotics into Peyer's patches[J/OL]. Science, 2021,7. doi:10.1126/sciadv.abf0677.
[30] Schluter J, Peled JU, Taylor BP, et al. The gut microǒ-biota is associated with immune cell dynamics in humans[J].Nature,2020,588:303-307.
[31] Ansari S, Yamaoka Y. Helicobacter pylori virulence factors exploiting gastric colonization and its pathogenicity[J]. Toxins(Basel),2019,11:677-680.
[32] Chloe E. Atreya, Peter J.Turnbaugh,et al.Probing the tumor micro(b) environment[J]. Science, 2020,368:938-939.
[33] Neelapu SS. Managing the toxicities of CAR T-cell therapy[J].Hematolog Oncol,2019,37:48-52.